RT Journal Article
SR Electronic
T1 Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials
JF Canadian Medical Association Journal
JO CMAJ
FD Canadian Medical Association
SP 421
OP 429
DO 10.1503/cmaj.101685
VO 183
IS 4
A1 Wells, George
A1 Parkash, Ratika
A1 Healey, Jeffrey S.
A1 Talajic, Mario
A1 Arnold, J. Malcolm
A1 Sullivan, Shannon
A1 Peterson, Joan
A1 Yetisir, Elizabeth
A1 Theoret-Patrick, Patricia
A1 Luce, Marilynn
A1 Tang, Anthony S.L.
YR 2011
UL http://www.cmaj.ca/content/183/4/421.abstract
AB Background Studies of cardiac resynchronization therapy in addition to an implantable cardioverter defibrillator in patients with mild to moderate congestive heart failure had not been shown to reduce mortality until the recent RAFT trial (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial). We performed a meta-analysis including the RAFT trial to determine the effect of cardiac resynchronization therapy with or without an implantable defibrillator on mortality. Methods We searched electronic databases and other sources for reports of randomized trials using a parallel or crossover design. We included studies involving patients with heart failure receiving optimal medical therapy that compared cardiac resynchronization therapy with optimal medical therapy alone, or cardiac resynchronization therapy plus an implantable defibrillator with a standard implantable defibrillator. The primary outcome was mortality. The optimum information size was considered to assess the minimum amount of information required in the literature to reach reliable conclusions about cardiac resynchronization therapy. Results Of 3071 reports identified, 12 studies (n = 7538) were included in our meta-analysis. Compared with optimal medical therapy alone, cardiac resynchronization therapy plus optimal medical therapy significantly reduced mortality (relative risk [RR] 0.73, 95% confidence interval [CI] 0.62–0.85). Compared with an implantable defibrillator alone, cardiac resynchronization therapy plus an implantable defibrillator significantly reduced mortality (RR 0.83, 95% CI 0.72–0.96). This last finding remained significant among patients with New York Heart Association (NYHA) class I or II disease (RR 0.80, 95% CI 0.67–0.96) but not among those with class III or IV disease (RR 0.84, 95% CI 0.69–1.07). Analysis of the optimum information size showed that the sequential monitoring boundary was crossed, which suggests no need for further clinical trials. Interpretation The cumulative evidence is now conclusive that the addition of cardiac resynchronization to optimal medical therapy or defibrillator therapy significantly reduces mortality among patients with heart failure.